Extra-airway vapor ablation for treating airway constriction in patients with asthma and COPD

Information

  • Patent Grant
  • 11129673
  • Patent Number
    11,129,673
  • Date Filed
    Tuesday, May 1, 2018
    6 years ago
  • Date Issued
    Tuesday, September 28, 2021
    2 years ago
Abstract
A vapor-based ablation method mitigates constriction of the airways for the treatment of asthma and COPD. A vapor ablation catheter is advanced along the airways, through the airway wall, and to an extra-airway target tissue. The position of the catheter is assessed to determine whether the catheter is in contact with the target tissue. In embodiments, the distal energy delivery section of the catheter is manipulated to contact an exterior surface of the target tissue, or to enter the target tissue. Once the position is confirmed, vapor is delivered to the target tissue through an egress port with a sufficient amount of energy to ablate the target tissue. The target tissue may vary and include smooth muscle surrounding the airways, and nerves that control the smooth muscle. Methods for treating lung cancer are also described including delivering a vapor at lung tumors and growths, and blood vessels feeding the lung tumors and growths.
Description
BACKGROUND OF THE INVENTION

Asthma and chronic obstructive pulmonary disease (COPD) are respiratory conditions affecting numerous people. People suffering from asthma and COPD experience airway constriction (bronchoconstriction) in the lungs, making breathing difficult, uncomfortable, and potentially life threatening.


Various approaches to treat patients with airway constriction include systemic and interventional-based techniques. Examples of systemic-based techniques include use of steroids and other anti-inflammatory drugs which work to reduce swelling and mucus production in the airways. However, prolonged use of inhaled corticosteroids has potential to cause side effects. Examples of potential side effects include impaired growth in children, decreased bone mineral density, skin thinning and bruising, and cataracts. Dahl R. “Systemic side effects of inhaled corticosteroids in patients with asthma,” Respir Med. 2006 August; 100(8):1307-17. Epub 2006 Jan. 18.


Examples of interventional-based techniques include bronchial thermoplasty in which radiofrequency (RF) energy is applied to the interior surface of the airway wall, heating the airway and reducing the amount of smooth muscle present in the airway wall. Cox G., M. D., McWilliams A., FitzGerald J. M., and Lam S. (2006). “Bronchial Thermoplasty for Asthma.” American Journal of Respiratory Critical Care Medicine 173: 965-969. Another example is targeted lung denervation in which RF energy is projected through the airway wall to ablate and permanently interrupt the function of the airway nerves. See Holaira™ Lung Denervation System (manufactured by Holaira Inc., Minneapolis, Minn.).


A shortcoming with the above described interventional-based techniques, however, is the temperature closer to the heat element shall increase more rapidly than the temperature farther from the heat element. The non-uniform temperature distribution increases the risk of collateral damage to non-target or healthy tissues near the heat source when trying to heat more remote target tissue.


Another shortcoming is that each technology is limited to ablating only one type of tissue: either the muscle (thermoplasty) or the nerve (targeted lung denervation).


Accordingly, there is still a need for minimally invasive approaches to effectively ablate extra-airway target lung regions while minimizing collateral damage to other structures.


There is also a need to more quickly and more effectively ablate the extra-airway structures.


SUMMARY OF THE INVENTION

A method for ablating a target tissue outside of an airway in a patient's lung comprises advancing a distal section of a catheter into contact with the target tissue outside of the airway. The position of the distal section of the catheter is assessed to determine whether the catheter is in contact with the target tissue. Vapor is delivered into the target tissue through an egress port with a sufficient amount of energy to ablate the target tissue.


In embodiments, vapor is directed at the nerves and or smooth muscles surrounding the constricted airways.


In embodiments, the distal section of the vapor delivery catheter has a face surface in which at least one egress port is located. The face surface is manipulated into a position such that the egress port is aimed towards the exterior surface of the target tissue (e.g., the nerves or smooth muscles surrounding the airway). The face surface can be further manipulated into a position such that the egress port is aimed towards and contacting the exterior surface of the target tissue.


In embodiments, the distal section of the catheter is adapted to penetrate the airway wall and be advanced to the target tissue. In other embodiments, the distal section of the catheter is advanced through a pre-existing hole, passageway, or tubular appliance towards the target tissue. Then, the target is ablated.


In embodiments, a method for treating cancer in a lung of a patient includes identifying a tumor in the lung; and identifying a blood vessel that feeds the tumor. The method further includes advancing a distal section of the vapor delivery catheter into the lung along an airway, and further advancing the distal section of the vapor delivery catheter from the airway into contact with the blood vessel outside of the airway. The position of the catheter is assessed to determine whether the catheter is in position to ablate the blood vessel. After the position of the catheter is confirmed, the method includes delivering vapor to the blood vessel through the egress port with a sufficient amount of energy to ablate the blood vessel.


In another embodiment, a method for ablating a target tissue outside of an airway in a patient's lung comprises advancing a distal section of a catheter into contact with the target tissue outside of the airway. The position of the distal section of the catheter is assessed to determine whether the catheter is in contact with the target tissue. Energy is delivered to the target tissue from the distal section sufficient to ablate the target tissue. The target tissue may be ablated or otherwise destroyed by causing target tissue's temperature to hit a lethal range beyond which the tissue is not functional or viable. In preferred embodiments, delivery of the energy is performed using a condensable vapor.


The description, objects and advantages of the present invention will become apparent from the detailed description to follow, together with the accompanying drawings.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 illustrates a human respiratory system;



FIGS. 2A, 2B illustrate an airway in the respiratory system in a normal and asthmatic state respectively;



FIG. 3 illustrates a bronchoscopic method for treating lung tissue;



FIG. 4 is a schematic illustration of a vapor generator;



FIG. 5 is an illustration of a vapor ablation catheter;



FIG. 6A is an illustration of a vapor ablation catheter advanced to a target tissue for treating asthma;



FIG. 6B is a cross sectional view of the airway anatomy and vapor ablation catheter shown in FIG. 6A taken along line 6B-6B;



FIG. 6C, FIG. 6D show a catheter delivering energy into (or within) a nerve and smooth muscle, respectively;



FIG. 7 is an illustration of a vapor ablation catheter being advanced into an extra-airway target tissue, resulting in motion of the airway;



FIG. 8 is a flowchart of a method for treating asthma;



FIG. 9 is an illustration of a vapor ablation catheter advanced into a blood vessel for treating lung cancer; and



FIG. 10 is a flowchart of a method for treating lung cancer.





DETAILED DESCRIPTION OF THE INVENTION

Before the present invention is described in detail, it is to be understood that this invention is not limited to particular variations set forth herein as various changes or modifications may be made to the invention described and equivalents may be substituted without departing from the spirit and scope of the invention. As will be apparent to those of skill in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has discrete components and features which may be readily separated from or combined with the features of any of the other several embodiments without departing from the scope or spirit of the present invention. In addition, many modifications may be made to adapt a particular situation, material, composition of matter, process, process act(s) or step(s) to the objective(s), spirit or scope of the present invention. All such modifications are intended to be within the scope of the claims made herein.


Methods recited herein may be carried out in any order of the recited events which is logically possible, as well as the recited order of events. Furthermore, where a range of values is provided, it is understood that every intervening value, between the upper and lower limit of that range and any other stated or intervening value in that stated range is encompassed within the invention. Also, it is contemplated that any optional feature of the inventive variations described may be set forth and claimed independently, or in combination with any one or more of the features described herein.


All existing subject matter mentioned herein (e.g., publications, patents, patent applications and hardware) is incorporated by reference herein in its entirety except insofar as the subject matter may conflict with that of the present invention (in which case what is present herein shall prevail). The referenced items are provided solely for their disclosure prior to the filing date of the present application.


Reference to a singular item, includes the possibility that there are plural of the same items present. More specifically, as used herein and in the appended claims, the singular forms “a,” “an,” “said” and “the” include plural referents unless the context clearly dictates otherwise. It is further noted that the claims may be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology as “solely,” “only” and the like in connection with the recitation of claim elements, or use of a “negative” limitation. Last, it is to be appreciated that unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.



FIG. 1 illustrates a human respiratory system 10. The respiratory system 10 resides within the thorax 12 that occupies a space defined by the chest wall 14 and the diaphragm 16. The human respiratory system 10 includes left lung lobes 44 and 46 and right lung lobes 48, 50, and 52.


The respiratory system 10 may be characterized by a tree-like structure formed of branched airways including the trachea 68; left and right main stem bronchus 20 and 22 (primary, or first generation) and lobar bronchial branches 24, 26, 28, 30, and 32 (second generation). Segmental and subsegmental branches further bifurcate off the lobar bronchial branches (third and fourth generation). Each bronchial branch and sub-branch communicates with a different portion of a lung lobe, either the entire lung lobe or a portion thereof.



FIGS. 2A, 2B illustrate cross sectional views of an airway in a normal state 72 and asthmatic state 72′, respectively. Smooth muscles 74 are shown axially spaced along the airway and are contracted in the asthmatic airway 72′. Nerves 76 communicate with the smooth muscles, and control movement of the smooth muscles 74. Thus, the nerves can affect the size or diameter of the airway passageway by causing the smooth muscles to constrict or expand. Blood vessels 78 are also shown in FIGS. 2A, 2B serving to transport blood therethrough.


Bronchoscopy Approach


FIG. 3 illustrates a bronchoscopic procedure in accordance with some embodiments of the present invention. FIG. 3 shows a bronchoscope 100 having a working channel into which an energy delivery catheter 200 is inserted. Bronchoscope 100 is inserted into a patient's lungs while the proximal portion of the energy delivery catheter 200 remains outside of the patient. Energy delivery catheter 200 is adapted to operatively couple to an energy generator 300 as further discussed below. Examples of energy delivery catheters include without limitation a condensable vapor ablation catheter as described herein.


Energy Generator


FIG. 4 is a schematic diagram of an energy generator 300 configured as a vapor generator. In embodiments, vapor generator is configured to deliver a controlled dose of vapor to one or more target lung tissues. Vapor generator 300 is adapted to convert a biocompatible liquid 301 (e.g. saline, sterile water or other biocompatible liquid), into a wet or dry vapor, which is then delivered to one or more target tissues. A wet vapor refers to a vapor that contains vaporous forms of the liquid as well as a non-negligible proportion of minute liquid droplets carried over with and held in suspension in the vapor. A dry vapor refers to a vapor that contains little or no liquid droplets. In general, vapor generator 300 is configured to have a liquid capacity between about 1000 to 2500 cc and configured to generate a vapor having a pressure between about 5-100 psig and temperatures between about 100-175° C.


In embodiments, vapor generator 300 is configured as a self-contained, medical-grade generator unit comprising at least a vaporizing unit 302, a vapor inlet 304, and a vapor outlet 306. The vaporizing unit 302 comprises a fluid chamber for containing a fluid 301, preferably a biocompatible, sterile fluid, in a liquid state. In embodiments, vapor outlet 306 is coupled to one or more pipes or tubes 314, which in turn are placed in fluid communication with an energy delivery catheter 200. Vapor flow from vapor generator 300 to a catheter (and specifically a vapor lumen of said catheter) is depicted as a vapor flow circuit 314 wherein flow of the vapor in circuit 314 is indicated by arrows 314 in FIG. 4. In a preferred embodiment, vapor generator is configured to deliver a repeatable dose of vapor to energy delivery catheter 200. Suitable doses of vapor range from 100 to 1000 calories.


Vaporizer unit 302 is configured to heat and vaporize a liquid contained therein. Other components can be incorporated into the biocompatible liquid 301 or mixed into the vapor. For example, these components can be used in order to control perioperative and/or post procedural pain, enhance tissue fibrosis, and/or control infection. Other constituents, for the purpose of regulating vapor temperatures and thus control extent and speed of tissue heating, can be incorporated; for example, in one implementation, carbon dioxide, helium, other noble gases can be mixed with the vapor to decrease vapor temperatures.


Vaporizing unit 302 is also shown having a fluid inlet 304 to allow liquid 301 to be added to the fluid chamber as needed. Fluid chamber can be configured to accommodate or vaporize sufficient liquid as needed to apply vapor to one or more target tissues. Liquid in vaporizing unit 302 is heated and vaporized and the vapor flows into vapor outlet 306. A number of hollow tubular shafts or pipes 314 are adapted to fluidly connect vapor outlet 306 to the catheter 200.


In embodiments, a flexible hollow tube or umbilical-like cord extends from the generator 300 and terminates in a handle (not shown). The handle is adapted to operatively couple to a variety of types of energy delivery catheters via a hub assembly (such as hub assembly 214 shown in FIG. 5 and discussed herein). In embodiments, the hub assembly or other connecting means is configured to allow for a secure, fluidly sealed, and quick release between the catheter and generator handle. Examples of suitable quick connect and release mechanisms include, without limitation, Luer Lock hub assemblies and fittings.


In embodiments, a catheter and vapor generator are configured to be directly coupled to one another via mating connectors. Vapor delivery is controlled by the generator, a controller external to the generator, or actuating buttons and mechanisms on the catheter itself. For example, the catheter may comprise a handpiece portion to control vapor doses.


Preferably, there is little or no vapor-to-liquid transition during movement of the vapor through vapor flow circuit 314. Vapor flow through vapor flow circuit 314 is unidirectional (in the direction of arrows 314), accordingly one or more isolation valves 320 are incorporated in vapor flow circuit 314. Isolation valves 320, which are normally open during use of generator 300, serve to minimize vapor flow in a direction opposite that of the vapor flow circuit 314.


A priming line 330, branching from main vapor flow circuit 314, is provided to minimize or prevent undesirable liquid-state water formation during vapor flow through vapor flow circuit 314. Pressure and temperature changes along vapor flow circuit 314 can affect whether the vapor is sustainable in a vapor state or condensed back into a liquid. Priming line 330 is provided to equalize temperatures and/or pressures along vapor flow circuit 314 in order to minimize or prevent undesirable liquid-state transition of the vapor during its progression through vapor flow circuit 314. In one embodiment, an initial “purge” or “priming” procedure can be performed prior to delivery of a therapeutic vapor dose in order to preheat flow circuit 314 thus maintaining a constant temperature and pressure in the main vapor flow circuit 314 prior to delivery of a vapor to the target lung tissue.


As shown in FIG. 4, priming line 330 terminates at evaporator 332, which is adapted to either house undesirable liquid in a collection unit (not shown) located within generator 300. In one embodiment, collection unit is adapted to house the liquid until a user or clinician is able to empty said collection unit. Alternatively, evaporator 332 is configured to evaporate and expel said undesirable liquid into the ambient air. Baffle plates (not shown) or other like means can be incorporated in evaporator 332 to facilitate maximal vapor-to-liquid transition. It should be understood that other suitable evaporator configurations could be included to facilitate vapor-to-liquid transition during a priming procedure of lines 314.


A number of sensors, operatively connected to a controller, can be incorporated into vapor generator 300, for example, in the liquid chamber, or along any point in vapor flow circuit 314. Water level sensors, adapted to monitor the water level in the liquid chamber, can be included. These water level sensors are configured as upper and lower security sensors to sense or indicate when a liquid level in the fluid chamber is below or above a set fluid level. For example, if a water level in the fluid chamber falls below the level of a lower water control sensor, the controller can be configured to interrupt the operation of the vapor generator 300.


In yet another embodiment, pressure sensors, or manometers, can be included in vaporizing unit 302, or at various points along the vapor flow circuit 314, to measure the liquid or vapor pressures at various discrete locations and/or to measure vapor pressures within a defined segment along circuit 314. One or more control valves 320 can also be installed at various points in the vapor flow circuit 314 to control vapor flow, for instance, to control or increase the vapor flow or vapor flow rates in vapor flow circuit 314.


In yet another embodiment, a safety valve 322 can be incorporated into the liquid chamber of vaporizing unit 302 and coupled to a vapor overflow line 340 if the need for removing or venting vaporizing unit 302 arises during generator 300 operation.


Although the vapor generator is described above having various specific features, the components and configurations of the vapor generator and catheter systems may vary. Additional vapor ablation systems are described in, for example, U.S. Patent Publication No. 2015/0094607 to Barry et al., and U.S. Pat. No. 7,913,698 to Barry et al., and U.S. Pat. No. 8,322,335 to Barry et al., and U.S. Pat. No. 7,993,323 to Barry et al.


In other embodiments, a condensable vapor is created in the handle portion of the catheter system. Consequently, a separate vapor generator unit is not required. Systems including a resistive heater are described in, for example, U.S. Patent Publication No. 2016/0220297 to Kroon et al. and U.S. Patent Publication No. 2014/0276713 to Hoey et al. Indeed, embodiments of the invention include a wide range of mechanisms to create and transport vapor through the working catheter as described herein.


Vapor Ablation Catheter


FIG. 5 illustrates a vapor ablation catheter 200 in accordance with one embodiment of the invention. Catheter 200 is shown having a proximal section 202, intermediate section 204, and distal end section 206. Proximal section 202 can include a handpiece portion 212 and hub 214 which may be connected to the generator as described above. Intermediate section 204 is flexible and continues to distal end section 206. Examples of suitable materials for the catheter shaft include polyimide, PEBAX, silicone, PEEK, and stainless steel braiding.


The distal end section 206 is shown having a pointed tip and a plurality of egress ports 208 for vapor to be directed towards the target tissue. In embodiments, the tip is rigid, sharp, and adapted to penetrate tissue. Examples of suitable materials for the tip of the catheter include stainless steel, Nitinol, and PEEK. At least one egress port 208 is desirable, however, the number of egress ports may range from 1-20, and more preferably 6-12.


The shape of the egress port is shown as a circle. However, the shape and size of the egress ports may vary. In embodiments, the egress port has a circular shape and a diameter in the range of 0.1 to 2 mm.



FIG. 5 shows the egress ports 208 on one lateral surface, face, side, or facet of the tip. The vapor may thus be aimed in solely one direction. However, in other embodiments, the egress ports are spaced about the circumference of the distal end section such that the vapor may be directed radially in all directions from the shaft. In yet other embodiments, the egress port(s) are located on the end of the catheter tip and send the vapor in an axial direction.


Additional examples of vapor delivery catheter configurations are described in the literature. Another example of a vapor catheter having components and structures which may be combined with the subject invention is described in U.S. Pat. No. 8,444,636 to Shadduck and Hoey; and U.S. Patent Publication No. 2014/0025057 to Hoey and Shadduck. The catheter and tip configuration may vary widely and the invention is only intended to be limited as recited in the appended claims.


Asthma Treatment


FIG. 6A illustrates use of a vapor ablation catheter 200 to treat an asthmatic airway 82. The airway is shown in a constricted state due to the contraction of smooth muscles 74, and the condition is further exacerbated by the presence of an increased mucus layer 75.



FIG. 6A also shows catheter 200 having been advanced from the bronchoscope 100. Distal end section 206 is shown passing through the airway wall 82, between smooth muscle segments 74, and facing towards or in contact with nerve portion 76.



FIG. 6B is a cross section illustration of FIG. 6A, taken along line 6B-6B. Distal end section 206 of the catheter is shown advanced outside of the airway, and adjusted to face nerve portion 76. Egress ports 208 are shown aimed or directed towards the exterior surface of the nerve 76, and in some embodiments, the smooth muscle.


Vapor 205 is shown delivered from the egress ports 208 towards the nerve 76, and the smooth muscle 74 surrounding the outside of the airway. As mentioned herein, and without intending to be bound to theory, heating the nerve and smooth muscles surrounding the airway prevents the narrowing of the airway characteristic of an asthma attack.


It should also be appreciated that the embodiment shown in FIG. 6B demonstrates the distal end 206 being located in close proximity (e.g., within 5 mm) and perhaps even making contact with the exterior surface of the nerve 76. The vapor 205 is directed towards the target and, due to its gaseous state, tends to follow the target airway boundary, creating a safer, faster, and more precise energy delivery than previous methods (e.g., a heat source placed against the interior surface of the airway wall 82).



FIG. 6C and FIG. 6D show the catheter 200 delivering energy into (or within) the nerve 76 and smooth muscle 74, respectively. In embodiments, catheter distal section 206 has a needle-like configuration or otherwise sharp tip to penetrate and enter the targeted tissues. The vapor 205 is shown moving, or otherwise flowing through the targeted tissue and follows the boundary of the target tissue because of the presence of higher density cells on the margin or perimeter of the target tissue. The vapor thus moves quickly within the target tissue, and along its boundary, causing thermal ablation as described herein.


In embodiments, a method includes dispersing a vapor through a volume of a first tissue (or filling the first tissue structure with the vapor) with a dose sufficient to render the target tissue non-functional, or to destroy the tissue.


Assessing Catheter Location and Target Contact

In embodiments, as described further herein, methods include assessing the location of the distal end section of the catheter to determine whether the distal section of the catheter is in contact (or otherwise properly located) relative to the target tissue. Nonlimiting examples of target tissue include nerves, smooth muscle, airway tissue, blood vessels as well as tumors, infected or diseased tissues, lymph nodes and tissue growths whether cancerous or benign.


Techniques for confirming or assessing the position of the distal end section may vary. In embodiments, assessing the location of the distal end section may be performed using noninvasive imaging means, and guidance software. Nonlimiting examples of guidance techniques include video or fluoroscopy based tracking and guidance, and electromagnetic based guidance via use of transponders or other sensors or transmitters. Systems may be employed to track the location of the distal end section relative to previously obtained image data of the patient. Examples of tracking and guidance techniques are described in U.S. Pat. No. 7,233,820 to Gilboa; U.S. Pat. No. 7,756,563 to Higgins et al.; U.S. Pat. No. 7,889,905 to Higgins et al.; U.S. Pat. No. 9,265,468 to Rai et al.; and U.S. Patent Publication No. 20160180529 to Rai et al. See, e.g., the Superdimension™ Navigation System, manufactured by Medtronic (Minneapolis, Minn.), and the Archimedes™ System, manufactured by Broncus Medical, Inc., (San Jose, Calif.).


Additionally, in embodiments, the physician can preoperatively plan one or more routes through the airways to the target tissue. An entire pathway or route may be planned from the mouth or nasal passageway, through the airways, and to the target tissue outside of the airway. Then, the pre-planned or pre-determined route may be used during the procedure to guide the physician. One of the above described guidance techniques can be used to assess the location of the catheter as it is advanced into the target position. Once the position of the catheter is confirmed to be at the proper location, the catheter is activated to ablate the targeted tissue. Examples of a route planning techniques are described in U.S. Pat. No. 9,037,215 and U.S. Patent Publication No. 2009/0156895, both to Higgins et al. See also the LungPoint® Planner, manufactured by Broncus Medical, Inc., (San Jose, Calif.).


Additionally, in embodiments, automatic and semi-automatic compiling and evaluation of lung image data, image reconstruction, and display is performed. See, e.g., U.S. Pat. No. 9,037,215 to Higgins et al., and U.S. Patent Publication Nos. 2009/0156895 and 2010/0310146 both to Higgins et al., and 2014/0275952 to Monroe et al. Additionally, assessment of the position of the catheter may be performed via empirical techniques including observing movement of the nerve/airway and/or measuring nerve activity as the catheter tip is moved into and out of contact with the nerve (namely, hitting or probing).


In embodiments, and with reference to FIG. 7, the distal end section 206 of the catheter 200 is shown advanced through an opening in the airway wall 82, and a needle tip inserted into the nerve 76. The physician may visually observe movement (B) of the airway wall in response to advancement (A) of the catheter towards the nerve 76. Airway spasms may be visible by a bronchoscope positioned in the airway. Movement or spasms can be indicative of the tip 206 penetrating or making contact with the nerve.


Additionally, external sensors may interrogate or confirm contact between the distal tip and the nerve or smooth muscle. Such tests record or sense nerve activity or electrical activity in a minimally or noninvasive manner. Nonlimiting examples of external sensors include electromyography (EMG) sensors and systems. In embodiments, a surface-type EMG sensor is affixed to the skin of the patient to monitor nerve activity.



FIG. 8 is a flowchart describing a method for treating asthma 500 in accordance with one embodiment of the invention.


Step 510 states to identify a target tissue outside of the airway in a lung. As described above, examples of target tissue include a nerve and airway smooth muscle. Noninvasive means may be applied to view and identify the target.


Step 520 states to advance a distal section of a vapor delivery catheter to the target tissue. In embodiments, the distal section of the catheter is a sharpened tip which is adapted to penetrate the airway wall, creating an opening through the airway wall. The energy delivery tip is further advanced outside of the airway towards the target tissue. In embodiments, the catheter distal section is advanced into the target tissue, or in contact with the target tissue.


In embodiments, the catheter distal section is curved about, or flush with the nerve, or otherwise manipulated until the egress ports face or are aimed at the nerve tissue.


In other embodiments, the catheter distal section is advanced through a pre-existing opening, passageway, or ancillary appliance or instrument channel. Techniques and instruments for creating passageways and installing working tubes through the airway wall, and for performing procedures through the passageways, are described in, for example, U.S. Pat. Nos. 8,409,167 and 8,709,034.


Step 530 states to assess the location of the distal section of the catheter. Assessing may be performed by determining whether the energy delivery section is in contact with the target tissue to be ablated using a number of different techniques as described herein. In embodiments, confirmation of the location of the distal section of the vapor delivery catheter is performed by probing the target tissue with the catheter and visually observing movement of the tissue structure commanded by the nerve. However, a wide variety of techniques may be employed to assess the location of the vapor delivery catheter.


Step 540 states to deliver vapor with an amount of energy to ablate the tissue. As described herein, the amount and type of energy (flow rate, composition, temperature) may be controlled by the system and based on the characteristics of the tissue such as volume, mass, density, location, and type of tissue. Example quantities or amounts of energy range from 10 to 2000 calories, and in embodiments 100 to 1000 calories. The vapor is delivered from the egress ports into the tissue. The vapor tends to follow the boundary of the airway, raising the temperature uniformly across the target tissue as opposed to developing a large temperature gradient. Ablating the target tissue (e.g., the nerve and/or smooth muscles surrounding the airway) serves to alleviate the conditions associated with asthma as described herein.


In embodiments, the catheter may be moved to additional target locations along the airway, or a different airway and the procedure repeated.


Additionally, in embodiments, the location of the catheter is assessed, and if the catheter is not in proper position, the catheter is further manipulated and the step of assessing is repeated. The process may be repeated until the catheter is ultimately in the desired position.


Lung Cancer Treatment


FIG. 9 illustrates a method for treating a lung tumor 400 in accordance with one embodiment of the invention. At least one blood vessel 410 is shown feeding the tumor 400. A specific blood vessel may be identified prior to the procedure as a candidate target tissue to ablate, thereby cutting off the blood supply to the tumor, and ultimately destroying the tumor. Identifying the blood vessel may be carried out as described above in connection with identifying the target tissues. Image data of a patient may be used to identify targets prior to the procedure. Alternatively, real-time diagnostic means may identify the target tissues including, for example, imaging ultrasound, Doppler, and fluoroscopy.



FIG. 9 also shows a distal section of an energy delivery catheter 420 advanced from the airway 430 to the target blood vessel 410 outside of the airway.


The tip is shown contacting or flush with the surface of the blood vessel. As described above, location of the tip relative to the vessel is assessed or confirmed prior to ablating the tissue. Once the location of the energy delivery section is confirmed, the instrument is activated.


In embodiments, the catheter tip can feature an atraumatic shape, and at least one vent for directing vapor to the blood vessel. The steps of the method may be repeated to ablate several vessels serving to stop all blood flow to the tumor, and causing the tumor to be destroyed. Additionally, by delivering the vapor as described above, heat is applied directly and evenly across the targeted blood vessel, and collateral damage to nearby tissue is avoided.



FIG. 10 is a flowchart setting forth a method 600 for treating cancer in accordance with an embodiment of the invention.


Step 610 states to identify a tumor and blood vessel feeding the tumor. Identifying the tumor and blood vessel may be performed preoperatively based on image data as described herein.


The tissue structures may be identified in images manually by the physician or the image data may be analyzed semi-automatically by computer systems to identify tissue structures, and present or display candidate structures. Examples of segmentation techniques are described in, for example, US 2010/0310146 to Higgins et al.


Additionally, in embodiments, as described herein, an entire pathway or route may be planned from the mouth or nasal passageway, through the airways, and to the target tissue outside of the airway. Providing a pre-planned route to the extra-airway target helps the physician reach the target.


Step 620 states to advance a vapor delivery catheter from the airway to the blood vessel. As described herein, the distal section of the catheter may be manipulated towards the blood vessel under image guidance.


Step 630 states to assess the location of the catheter to determine whether the apparatus is in position to ablate the tissue. In embodiments, the desired location of the catheter is towards or facing the blood vessel. In embodiments, the desired location of the catheter is in contact with the blood vessel. As described herein, the location of the distal section of the catheter may be assessed using image guidance or other means.


Additionally, tracking or guidance systems as descried herein may be employed to show real-time movement and location information of the catheter. In embodiments, guidance systems indicate the real-time location of the catheter, a path to follow, and a target to aim and move towards. Thus, one may confirm position using the tracking system prior to activating vapor delivery.


Step 640 states to deliver vapor to the feeder blood vessel, leading to the destruction of the tumor. By delivering the vapor as described above, heat is applied directly and evenly across the targeted blood vessel, and collateral damage to nearby tissue is avoided. The process may be repeated to ablate several vessels serving to stop all blood flow to the tumor, causing the tumor to be destroyed.


Other Embodiments

The shape and configuration of the catheter may vary widely. In embodiments, the distal section of the energy delivery catheter includes a discrete surface area, structure, or element from which the energy is sent to the target tissue. In embodiments, the distal section of the energy deliver catheter is in the form of a thin wire.


In embodiments, shape memory materials may be employed to provide a predetermined shape when released from a constrained member.


Additionally, control members such as pull wires may be incorporated into the catheter to adjust the curvature of the distal section such that the distal section may be steered to cover an exterior surface of the nerve and smooth muscle.


Other modifications and variations can be made to the disclosed embodiments without departing from the subject invention. It is intended that features, steps, and components of the above described embodiments may be combined in any way or order except where exclusive of one another.

Claims
  • 1. A method for treating airway constriction in a lung of a patient, the airway having an airway wall and an exterior surrounded by a target tissue, the method comprising: providing a vapor delivery catheter, the vapor delivery catheter comprising a proximal section, an intermediate section, and a distal section comprising at least one egress port and a distal tip;advancing the distal section of the vapor delivery catheter along said airway;manipulating the distal section of the vapor delivery catheter from a location inside said airway through the airway wall to a position outside of the airway;assessing the position of the distal section of the vapor delivery catheter wherein the assessing is performed by hitting the target tissue outside of the airway with the distal tip of the vapor delivery catheter and evaluating constriction movement within the airway responsive to the hitting; anddelivering vapor into the target tissue from the at least one egress port to ablate the target tissue, wherein the step of delivering is performed by directing the vapor directly at an exposed surface of the target tissue.
  • 2. The method of claim 1, comprising adjusting the position of the distal section of the vapor delivery catheter after the assessing step, and prior to the delivering step.
  • 3. The method of claim 1, wherein the assessing step is also based on a nerve activity monitor.
  • 4. The method of claim 1, wherein the vapor causes heat to be applied directly and uniformly across the target tissue.
  • 5. The method of claim 1, further comprising creating an opening through the airway wall, through which the distal section of the vapor delivery catheter is advanced towards the target tissue.
  • 6. The method of claim 5, wherein the creating is performed with the vapor delivery catheter.
  • 7. The method of claim 1, wherein the target tissue is a nerve responsible for controlling movement of muscles associated with airway motion.
  • 8. The method of claim 1, wherein the distal section of the vapor delivery catheter comprises a face surface in which the at least one egress port is located.
  • 9. The method of claim 8, wherein the face surface is manipulated into said position such that the at least one egress port is aimed towards an exterior surface of the target tissue.
  • 10. The method of claim 1, wherein the distal section of the vapor delivery catheter is a rigid needle having a sharp tip.
  • 11. The method of claim 1, wherein the at least one egress port comprises a plurality of egress ports.
  • 12. The method of claim 1, further comprising creating an opening through the airway wall, through which the distal section of the vapor delivery catheter is advanced towards the target tissue, and installing a tubular appliance in the opening in the airway wall, through which the distal section of the vapor delivery catheter is advanced towards the target tissue.
  • 13. A method for treating airway constriction in a lung of a patient arising from asthma or COPD by ablating a target tissue located on an exterior of the airway, the method comprising: providing an elongate energy delivery catheter comprising a proximal section, an intermediate section, and a distal section and a distal tip;advancing the distal section of the energy delivery catheter along the airway, through an opening in a wall of the airway, and to a position outside the airway;assessing the position of the distal section of the vapor delivery catheter wherein the assessing is performed by moving the distal tip into and out of physical contact with the target tissue outside of the airway and evaluating constriction movement within the airway responsive to the physical contact;adjusting said position based on the assessing step, such that energy delivery is aimed towards the target tissue probed in the assessing step; anddelivering energy to or within the target tissue from the distal section of the energy delivery catheter to ablate the target tissue.
  • 14. The method of claim 13, wherein the energy delivery catheter comprises a working surface or face portion along the distal section, and the working surface or face portion comprises at least one egress port from which the energy is sent to the target tissue.
  • 15. The method of claim 14, wherein the target tissue is a nerve to control smooth muscle.
  • 16. The method of claim 13, wherein the step of delivering energy comprises delivering a vapor.
  • 17. The method of claim 13, wherein the assessing step is also based on imaging.
  • 18. The method of claim 13, wherein the delivering step is carried out by sending vapor along a boundary of the target tissue.
  • 19. The method of claim 13, wherein the airway is second or greater generation airway.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority to provisional application No. 62/502,050, filed May 5, 2017, and entitled “EXTRA-AIRWAY VAPOR ABLATION FOR TREATING AIRWAY CONSTRICTION IN PATIENTS WITH ASTHMA AND COPD.”

US Referenced Citations (257)
Number Name Date Kind
408899 Small Aug 1889 A
1719750 Bridge Jul 1929 A
3507283 Thomas, Jr. Apr 1970 A
3880168 Berman Apr 1975 A
4026285 Jackson May 1977 A
4713060 Riuli Dec 1987 A
4713460 Riuli Dec 1987 A
4773410 Blackmer Sep 1988 A
4793352 Eichenlaub Dec 1988 A
4915113 Holman Apr 1990 A
4950266 Sinofsky Aug 1990 A
5006119 Acker Apr 1991 A
5011566 Hoffman Apr 1991 A
5084043 Hertzmann Jan 1992 A
5112328 Taboada May 1992 A
5158536 Sekins Oct 1992 A
5263951 Spears Nov 1993 A
5331947 Shtuman Jul 1994 A
5334190 Seiler Aug 1994 A
5348551 Spears Sep 1994 A
5352512 Hoffman Oct 1994 A
5424620 Cheon Jun 1995 A
5462521 Brucker Oct 1995 A
5500012 Brucker Mar 1996 A
5503638 Cooper Apr 1996 A
5524620 Rosenschein Jun 1996 A
5529076 Schachar Jun 1996 A
5549628 Cooper Aug 1996 A
5562608 Sekins Oct 1996 A
5575803 Cooper Nov 1996 A
5591157 Hennings Jan 1997 A
5620440 Heckele Apr 1997 A
5695507 Auth Dec 1997 A
5735811 Brisken Apr 1998 A
5752965 Francis May 1998 A
5755753 Knowlton May 1998 A
5782914 Schankereli Jul 1998 A
5800482 Pomeranz Sep 1998 A
5824703 Clark Oct 1998 A
5827268 Lauger Oct 1998 A
5913856 Chia Jun 1999 A
5957919 Laufer Sep 1999 A
5964752 Stone Oct 1999 A
5972026 Laufer Oct 1999 A
5986662 Argiro Nov 1999 A
5989445 Wise Nov 1999 A
6032077 Pomeranz Feb 2000 A
6053909 Shadduck Apr 2000 A
6059011 Giolo May 2000 A
6083255 Laufer Jul 2000 A
6099251 LaFleur Aug 2000 A
6102037 Koch Aug 2000 A
6113722 Hoffman Sep 2000 A
6130671 Argiro Oct 2000 A
6131570 Schuster Oct 2000 A
6139571 Fuller Oct 2000 A
6156036 Sussman Dec 2000 A
6162232 Shadduck Dec 2000 A
6179805 Sussman Jan 2001 B1
6194066 Hoffman Feb 2001 B1
6200333 Laufer Mar 2001 B1
6210404 Shadduck Apr 2001 B1
6219059 Argiro Apr 2001 B1
6273907 Laufer Aug 2001 B1
6283988 Laufer Sep 2001 B1
6283989 Laufer et al. Sep 2001 B1
6299633 Laufer Oct 2001 B1
6300150 Venkatasubramanian Oct 2001 B1
6312474 Francis Nov 2001 B1
6327505 Medhkour Dec 2001 B1
6394949 Crowley May 2002 B1
6398759 Sussman Jun 2002 B1
6398775 Perkins Jun 2002 B1
6409723 Edwards Jun 2002 B1
6411852 Danek et al. Jun 2002 B1
6458231 Wapner Oct 2002 B1
6468313 Claeson Oct 2002 B1
6488673 Laufer et al. Dec 2002 B1
6493569 Medhkour Dec 2002 B2
6508816 Shadduck Jan 2003 B2
6527761 Softesz Mar 2003 B1
6575929 Sussman Jun 2003 B2
6579270 Sussman Jun 2003 B2
6585639 Kotmel Jul 2003 B1
6588613 Pechenik Jul 2003 B1
6589201 Sussman Jul 2003 B1
6592594 Rimbaugh Jul 2003 B2
6599311 Biggs Jul 2003 B1
6610043 Ingenito Aug 2003 B1
6629951 Laufer Oct 2003 B2
6652594 Francis Nov 2003 B2
6653525 Ingenito Nov 2003 B2
6669694 Shadduck Dec 2003 B2
6676628 Sussman Jan 2004 B2
6679264 Deem Jan 2004 B1
6682520 Ingenito Jan 2004 B2
6692494 Cooper et al. Feb 2004 B1
6712812 Roschak Mar 2004 B2
6719738 Mehier Apr 2004 B2
6755794 Soukup Jun 2004 B2
6770070 Balbierz Aug 2004 B1
6776765 Soukup Aug 2004 B2
6860847 Alferness Mar 2005 B2
6885888 Rezai Apr 2005 B2
6901927 Deem Jun 2005 B2
6904909 Andreas Jun 2005 B2
6907881 Suki Jun 2005 B2
6911028 Shadduck Jun 2005 B2
6986769 Nelson Jan 2006 B2
6997189 Biggs Feb 2006 B2
7022088 Keast Apr 2006 B2
7027869 Danek et al. Apr 2006 B2
7031504 Argiro Apr 2006 B1
7083612 Littrup Aug 2006 B2
7128748 Mooradian Oct 2006 B2
7136064 Zuiderveld Nov 2006 B2
7144402 Kuester, III Dec 2006 B2
7144588 Oray Dec 2006 B2
7174644 Critelli et al. Feb 2007 B2
7175644 Cooper et al. Feb 2007 B2
7192400 Campbell Mar 2007 B2
7198635 Daneck Apr 2007 B2
7233820 Gilboa Jun 2007 B2
7235070 Vanney Jun 2007 B2
7335195 Mehier Feb 2008 B2
7347859 Garabedian Mar 2008 B2
7412977 Fields Aug 2008 B2
7422563 Roschak Sep 2008 B2
7422584 Loomas Sep 2008 B2
7425212 Danek et al. Sep 2008 B1
7462162 Phan Dec 2008 B2
7628789 Soltesz Dec 2009 B2
7708712 Phan May 2010 B2
7740017 Daneck Jun 2010 B2
7756563 Higgins et al. Jul 2010 B2
7778704 Rezai Aug 2010 B2
7815590 Cooper Oct 2010 B2
7819908 Ingenito Oct 2010 B2
7889905 Higgins et al. Feb 2011 B2
7906124 Laufer Mar 2011 B2
7913698 Barry Mar 2011 B2
7913898 Barry et al. Mar 2011 B2
7985187 Wibowo Jul 2011 B2
7993323 Barry et al. Aug 2011 B2
8002740 Willink Aug 2011 B2
8088127 Mayse et al. Jan 2012 B2
8172827 Deem May 2012 B2
8187269 Shadduck May 2012 B2
8251070 Daneck Aug 2012 B2
8292882 Daneck Oct 2012 B2
8322335 Barry et al. Dec 2012 B2
8409167 Roschak Apr 2013 B2
8444636 Shadduck et al. May 2013 B2
8585645 Barry Nov 2013 B2
8608724 Roschak Dec 2013 B2
8628495 Horton et al. Jan 2014 B2
8709034 Keast et al. Apr 2014 B2
8734380 Barry May 2014 B2
8784400 Roschak Jul 2014 B2
8858549 Shadduck Oct 2014 B2
8900223 Shadduck Dec 2014 B2
9037215 Higgins et al. May 2015 B2
9050076 Barry et al. Jun 2015 B2
9133858 Macchia et al. Sep 2015 B2
9265468 Rai et al. Feb 2016 B2
9913969 Roschak Mar 2018 B2
10064697 Sharma et al. Sep 2018 B2
20020077516 Flanigan Jun 2002 A1
20020111386 Michael et al. Aug 2002 A1
20020112723 Schuster et al. Aug 2002 A1
20020177846 Muller Nov 2002 A1
20030099279 Venkatasubramanian et al. May 2003 A1
20030181922 Alferness Sep 2003 A1
20030233099 Danaek et al. Dec 2003 A1
20040031494 Danek et al. Feb 2004 A1
20040038868 Ingenito Feb 2004 A1
20040047855 Ingenito Mar 2004 A1
20040055606 Hendricksen Mar 2004 A1
20040068306 Shadduck Apr 2004 A1
20040199226 Shadduck Oct 2004 A1
20040200484 Springmeyer Oct 2004 A1
20040244803 Tanaka Dec 2004 A1
20050016530 McCutcheon Jan 2005 A1
20050066974 Fields Mar 2005 A1
20050166925 Wilson Aug 2005 A1
20050171396 Pankratov Aug 2005 A1
20050171582 Matlock Aug 2005 A1
20050203483 Perkins Sep 2005 A1
20050215991 Altman Sep 2005 A1
20050222485 Shaw Oct 2005 A1
20060004400 McGurk Jan 2006 A1
20060047291 Barry Mar 2006 A1
20060100619 McClurken May 2006 A1
20060130630 Barry Jun 2006 A1
20060135955 Shadduck Jun 2006 A1
20060162731 Wondka Jul 2006 A1
20060200076 Gonzalez Sep 2006 A1
20060224154 Shadduck Oct 2006 A1
20070032785 Diederich Feb 2007 A1
20070036417 Argiro Feb 2007 A1
20070068530 Pacey Mar 2007 A1
20070091087 Zuiderveld Apr 2007 A1
20070092864 Reinhardt Apr 2007 A1
20070102011 Danek May 2007 A1
20070106292 Kaplan May 2007 A1
20070109299 Peterson May 2007 A1
20070112349 Danek May 2007 A1
20070118184 Danek May 2007 A1
20070137646 Weinstein Jun 2007 A1
20070293853 Truckai Dec 2007 A1
20080033493 Deckman Feb 2008 A1
20080132826 Shadduck Jun 2008 A1
20080249439 Tracey et al. Oct 2008 A1
20090043301 Jarrard Feb 2009 A1
20090118538 Pizzocaro et al. May 2009 A1
20090138001 Barry et al. May 2009 A1
20090149646 Hoey Jun 2009 A1
20090149846 Hoey et al. Jun 2009 A1
20090149897 Dacey, Jr. et al. Jun 2009 A1
20090156895 Higgins et al. Jun 2009 A1
20090192508 Laufer et al. Jul 2009 A1
20090216220 Hoey Aug 2009 A1
20090306640 Glaze et al. Dec 2009 A1
20090306644 Mayse Dec 2009 A1
20090312753 Shadduck Dec 2009 A1
20100094270 Sharma Apr 2010 A1
20100204688 Hoey Aug 2010 A1
20100256714 Springmeyer Oct 2010 A1
20100262133 Hoey Oct 2010 A1
20100310146 Higgins et al. Dec 2010 A1
20110077628 Hoey Mar 2011 A1
20110118725 Mayse May 2011 A1
20110160648 Hoey Jun 2011 A1
20110257644 Barry Oct 2011 A1
20110270031 Frazier Nov 2011 A1
20110301587 Deem Dec 2011 A1
20110319958 Simon et al. Dec 2011 A1
20120016363 Mayse Jan 2012 A1
20120016364 Mayse Jan 2012 A1
20120289776 Keast Nov 2012 A1
20130006231 Sharma Jan 2013 A1
20130267939 Barry et al. Oct 2013 A1
20130324987 Leung et al. Dec 2013 A1
20140025057 Hoey et al. Jan 2014 A1
20140275952 Monroe et al. Sep 2014 A1
20140276713 Hoey et al. Sep 2014 A1
20150094607 Barry et al. Apr 2015 A1
20150230852 Barry Aug 2015 A1
20160180629 Rai et al. Jun 2016 A1
20160220297 Kroon et al. Aug 2016 A1
20160287307 Clark Oct 2016 A1
20160310200 Wang Oct 2016 A1
20160374710 Sinelnikov et al. Dec 2016 A1
20180036084 Krimsky Feb 2018 A1
20180318002 Barry et al. Nov 2018 A1
20190069948 Herth et al. Mar 2019 A1
20190343579 Tandri et al. Nov 2019 A1
Foreign Referenced Citations (30)
Number Date Country
721086 Jun 2000 AU
1003582 Feb 2003 EP
1143864 Feb 2004 EP
1173103 Oct 2005 EP
1326549 Dec 2005 EP
1326548 Jan 2006 EP
1485033 Aug 2009 EP
200011927 Mar 2000 WO
200102042 Jan 2001 WO
2002069821 Sep 2002 WO
2003070302 Aug 2003 WO
2003086498 Oct 2003 WO
2005025635 Mar 2005 WO
2005102175 Nov 2005 WO
2006003665 Jan 2006 WO
2006052940 May 2006 WO
2006053308 May 2006 WO
2006053309 May 2006 WO
2006080015 Aug 2006 WO
2006116198 Nov 2006 WO
2008051706 May 2008 WO
2009009236 Jan 2009 WO
2009009398 Jan 2009 WO
2009015278 Jan 2009 WO
2009137819 Nov 2009 WO
2010042461 Apr 2010 WO
2011056684 May 2011 WO
2011060201 May 2011 WO
2011060200 May 2011 WO
2011127216 Oct 2011 WO
Non-Patent Literature Citations (38)
Entry
Becker, et al.; Lung volumes before and after lung volume reduction surgery; Am J Respir Crit Care Med; vol. 157; pp. 1593-1599; (1998) Oct. 28, 1997.
Carpenter III et al.; Comparison of endoscopic cryosurgery and electrocoagulation of bronchi; Trans. Amer. Acad. Opth., vol. 84; No. 1; pp. ORL-313-ORL-323; Jan. 1977.
clinical trials.gov.; Study of the AeriSeal System for HyPerinflation Reduction in Emphysema; 4 pages; Nov. 5, 2014; retrieved from the internet (http://clinicaltrials.gov/show/N.
Coda, et al., “Effects of pulmonary reventilation on gas exchange after cryolytic disobstruction of endobronchial tumors,” Minerva Medical, vol. 72, pp. 1627-1631, Jun. 1981.
Delaunois; Anatomy and physiology of collateral respiratory pathways; Eur. Respir. J.; 2(9); pp. 893-904; Oct. 1989.
Eyal et al.; The acute effect of pulmonary burns on lung mechanics and gas exchange in the rabbit; Br. J. Anaesth.; vol. 47; pp. 546-552; (year of publication is sufficiently, Date: 1975.
Ferlay et al.; GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10.
Fishman et al., A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema, N Engl J Med, vol. 348, No. 21, pp. 2059-2073, May 22, 2003.
Goldberg et al.; Radiofrequency tissue ablation in the rabbit lung: Efficacy and complications; Acad. Radiol.; vol. 2; pp. 776-784; Sep. 1995.
Herth et al., Efficacy predictors of lung volume reduction with zephyr valves in a european cohort, Eur.Respir. J.: 39(6); pp. 1334-1342, Jun. 2012.
Homasson, et al., “Bronchoscopic cryotherapy for airway strictures caused by tumors,” Chest, vol. 90, No. 2, Aug. 1986.
Kinsella, et al., “Quantitation of emphysema by computer tomography useing a densitymask program and correlation with pulmonary function tests,” Chest 97(2), Feb. 1990.
Looga, R., “Mechanism of changes in the respiratory and cardiovascular reflexes from the lungs associated with intrapulmonary steam burns,” Eng.Trans from Byulleten Experimental noi Biologii I Meditsiny: vol. 6, No. 6, Jun. 1966.
Marasso, et al., “Cryosurgery in bronchoscopic treatment of tracheobrachial stenosis,” Chest, vol. 103, No. 2, Feb. 1993.
Marasso, et al., “Radiofrequency resection of bronchial tumors in combination with cryotherapy; evaluation of a new technique,” Thorax, vol. 53, 1998.
Mathur, et al., “Fiberoptic bronchoscopic cryotherapy in the management of trachebronchial obstruction,” Chest, vol. 110, No. 3, Sep. 1996.
Morice, et al., “Endobrinchial argon plasma coagulation for treatment of hemotysis and neoplastic airway obstruction,” Chest, vol. 119, No. 3, Mar. 2001.
Moritz, et al., “The effects of inhaled heat on the air passage and lungs,” American J. of Pathology, vol. XXI, 1944.
Moulding, et al., “Preliminary studies for achieving transcervical oviduct occlusion by hot water or low pressure steam,” Advances in Planned Parenthood, vol. 12 No. 2, 1977.
National Lung Screening Trial Research Team, “Reduced Lung Cancer mortality with low dose computed tomographic screening,” N. Eng. J.Med, 365(5), Aug. 2011.
Pracht, Adam, “VIDA takes new approach,” Iowa City Press Citizen, Sep. 12, 2005.
Quin, J., “Use of neodymium yttrium aluminum garnet laser in long term palliation of airway obstruction,” Connecticut Medicine, vol. 59, No. 7, Jul. 1995.
Sciurba et al., “A randomized study of endobronchial valves for advanced emphysema,” N.Eng J. Med, 363(13), Sep. 2010.
Shah, et al., “Collateral ventilation and selection of techniques for bronchscopic lung volume reduction,” Thorax, 67 (4), Apr. 2012.
Slebos, et al., “Bronchoscopic lung volume reduction coil treatment of patients with sever heterogeneous emphysema,” Chest, 142(3), Sep. 2012.
Sutedja, et al, “Bronchoscopic treatment of lung tumors,” Elsevier, Lung Cancer, Jul. 11, 1994.
Van De Velde, “Vapo-cauterization of the uterus,” Amer.J.Med, Sci vol. CXVII, 1899.
Vorre, et al., “Morphology of tracheal scar after resection with C02 laser and high-frequency cutting loop,” Acta Otolarynaol (Stockh), vol. 107, 1989.
Tschirren, “Interthoracic Airway Trees: Segmentation and Airway Morphology Analysis from Low Dose CT Scans,” IEEE Transactions on Medical Imaging, vol. 24, No. 12, 2005.
Kang, Li, “Efficient optimal net surface detection for image segmentation—from theory to practice,” M.Sc.Thesis, The University of Iowa, Dec. 2003.
Tschirren, J., “Segmentation, anatomical labeling, branchpoint matching, and quantitative analysis of human airway trees in volumetric CT images,” Ph.D, Thesis, The University of Iowa, Aug. 2003, Part 1.
Tschirren, J., “Segmentation, anatomical labeling, branchpoint matching, and quantitative analysis of human airway trees in volumetric CT images,” Ph.D. Thesis, The University of Iowa, Aug. 2003, Part 2.
Tschirren, J., “Segmentation, anatomical labeling, branchpoint matching, and quantitative analysis of human airway trees in volumetric CT images,” Ph.D. Thesis, The University of Iowa, Aug. 2003, Part 3.
Tschirren, J., “Segmentation, anatomical labeling, branchpoint matching, and quantitative analysis of human airway trees in volumetric CT images,” Slides from Ph.D. Defense, The University of Iowa, Jul. 10, 2003, Part 1.
Tschirren, J., “Segmentation, anatomical labeling, branchpoint matching, and quantitative analysis of human airway trees in volumetric CT images,” Slides from Ph.D. Defense, The University of Iowa, Jul. 10, 2003, Part 2.
Blacker, G. F.; Vaporization of the uterus; J. of Obstetrics and Gynaecology; vol. 33; pp. 488-511; 1902.
clinical trials.gov.; Study of the AeriSeal System for HyPerinflation Reduction in Emphysema; 4 pages; Nov. 5, 2014; retrieved from the internet (http://clinicaltrials.gov/show/NCT01449292).
Cox et al., “Bronchial Thermoplasty for Asthma.” American Journal of Respiratory Critical Care Medicine 173: 965-969 (2006).
Related Publications (1)
Number Date Country
20180318002 A1 Nov 2018 US
Provisional Applications (1)
Number Date Country
62502050 May 2017 US